SML0421

SB265610

≥98% (HPLC)

• Synonim(y): 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea, N-(2-Bromophenyl)-N′-(7-cyano-1H-benzotriazol-4-yl)urea, SB 265610
• Wzór empiryczny (zapis Hilla): C₁₄H₉BrN₆O
• Numer CAS: 211096-49-0
• Masa cząsteczkowa: 357.16
• NACRES: NA.77
• PubChem Substance ID: 329825416
• UNSPSC Code: 51111800
• MDL number: MFCD09971124
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to light brown
• solubility: DMSO: 15 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: Brc1ccccc1NC(=O)Nc2ccc(C#N)c3nn[nH]c23
• InChI: 1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)
• InChI key: SEDUMQWZEOMXSO-UHFFFAOYSA-N

Opis

Application

SB265610 has been used:

• as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)[1]
• as a CX-chemokine receptor type 1 (CXCR1) inhibitor to study its effect on the chemotactic activity of chemokines on inflammatory cells[2]
• as a CXCR2 antagonist to study its effect on migration of neutrophils to the rat brain[3]

Biochem/physiol Actions

SB265610 is a potent and selective CXCR2 chemokine receptor antagonist.

SB265610 is a potent and selective CXCR2 chemokine receptor antagonist. It has a Kd = 2.5 nM.

Features and Benefits

This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable